Benralizumab leads to sustained asthma control improvement after 1 year in real-life severe asthmatics.
A. Renner (Wien, Austria), K. Marth (Wien, Austria), K. Patocka (Wien, Austria), M. Idzko (Wien, Austria), W. Pohl (Wien, Austria)
Source: International Congress 2022 – Studies targeting IL-5 pathways in asthma
Session: Studies targeting IL-5 pathways in asthma
Session type: Thematic Poster
Number: 2139
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Renner (Wien, Austria), K. Marth (Wien, Austria), K. Patocka (Wien, Austria), M. Idzko (Wien, Austria), W. Pohl (Wien, Austria). Benralizumab leads to sustained asthma control improvement after 1 year in real-life severe asthmatics.. 2139
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|